M. De Martino
Medical University of Vienna
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by M. De Martino.
European Urology Supplements | 2015
Ilaria Lucca; M. De Martino; Sebastian L. Hofbauer; Nura Zamani; A. Briganti; S.F. Shariat; Tobias Klatte
Purpose Pretreatment measurements of systemic inflammatory response, including the Glasgow prognostic score (GPS), the neutrophil-to-lymphocyte ratio (NLR), the monocyte-to-lymphocyte ratio (MLR), the platelet-to-lymphocyte ratio (PLR) and the prognostic nutritional index (PNI) have been recognized as prognostic factors in clear cell renal cell carcinoma (CCRCC), but there is at present no study that compared these markers.
European Urology Supplements | 2010
Tobias Klatte; M. De Martino; Georg Schatzl; Mesut Remzi; Matthias Waldert; Peter Weibl; Andrea Haitel; Gero Kramer; M. Marberger
Objectives To study the putative significance of angiotensin I-converting enzyme (ACE) in renal cell carcinoma (RCC). Recent evidence has suggested that a 287-base pair insertion (I)/deletion (D) polymorphism (rs4646994) of the angiotensin I-converting enzyme (ACE) might be associated with cancer risk and progression. Methods The present case-control study accrued 383 subjects, including 210 with RCC and 173 age- and sex-matched healthy individuals without evidence or a history of cancer. Genomic DNA was extracted from the peripheral blood leukocytes. The ACE fragment containing the polymorphism was amplified using conventional polymerase chain reaction using specific primer pairs and subsequently genotyped using agarose gel electrophoresis. Results Overall, a DD genotype and D allele were more frequently noted in the patients with RCC than in the controls ( P = .042 and P = .045, respectively), and resulted from a greater frequency of DD and D in chromophobe RCC ( P = .023 and P = .020, respectively). In contrast, the genotype and allele distribution of the controls and patients with papillary or clear cell RCC was similar. The II genotype was not observed in any patient with chromophobe RCC. On multivariate logistic regression analysis, the ACE genotype was an independent risk factor for chromophobe RCC ( P = .012). Neither the ACE genotypes or alleles were associated with the tumor stage or grade. Conclusions The results of the present study have shown for the first time that the ACE insertion/deletion gene polymorphism rs4646994 might be linked with the development of chromophobe RCC. Neither the ACE genotypes nor the alleles were associated with RCC progression.
European Urology Supplements | 2015
Ilaria Lucca; S.F. Shariat; Morgan Rouprêt; Malte Rieken; Luis A. Kluth; Romain Mathieu; Harun Fajkovic; Alberto Briganti; Christian Seitz; Pierre I. Karakiewicz; M. De Martino; Yair Lotan; Marko Babjuk; Tobias Klatte
European Urology Supplements | 2008
Tobias Klatte; Jonathan W. Said; David Seligson; M. De Martino; Jeffrey LaRochelle; Brian Shuch; Fairooz F. Kabbinavar; A.S. Belldegrun; A.J. Pantuck
European Urology Supplements | 2016
Tobias Klatte; Ilaria Lucca; Sebastian L. Hofbauer; Carmen V. Leitner; M. De Martino; Mehmet Özsoy; Harun Fajkovic; S.F. Shariat
European Urology Supplements | 2016
Francesco Soria; M. De Martino; Carmen V. Leitner; Marco Moschini; S.F. Shariat; Tobias Klatte
European Urology Supplements | 2011
M. De Martino; Tobias Klatte; Andrea Haitel; M. Marberger
European Urology Supplements | 2011
M. De Martino; Tobias Klatte; Matthias Waldert; Mesut Remzi; Andrea Haitel; M. Marberger
European Urology Supplements | 2009
Tobias Klatte; Mesut Remzi; Jonathan W. Said; Andrea Haitel; Fairooz F. Kabbinavar; Matthias Waldert; M. De Martino; M. Marberger; A.S. Belldegrun; A.J. Pantuck
European Urology Supplements | 2009
Tobias Klatte; Christian Seitz; Matthias Waldert; M. De Martino; M. Marberger; Mesut Remzi